We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+4.22%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.22B
AUM Growth
+$986M
(+16%)
Cap. Flow
+$1.27B
Cap. Flow
% of AUM
17.6%
Top 10 Holdings %
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLYM
Climb Bio
CLYM
|
+$272M |
| 2 |
Cytek Biosciences
CTKB
|
+$226M |
| 3 |
Invivyd
IVVD
|
+$198M |
| 4 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$196M |
| 5 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$177M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$112M |
| 2 |
Novavax
NVAX
|
+$102M |
| 3 |
Curis
CRIS
|
+$57.6M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$56.4M |
| 5 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$51.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.06% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.7B
| $1.18B | 16.32% |
7,387,900
+581,559
| +9% | +$79.6M |
|
|
2
Novavax
NVAX
$1.21B
| $435M | 6.03% |
2,097,794
-462,124
| -18% | -$102M |
|
|
CLYM
3
Climb Bio
CLYM
$708M
| $236M | 3.28% |
+13,150,849
| New | +$272M |
|
|
4
Invivyd
IVVD
$164M
| $226M | 3.13% |
+5,340,130
| New | +$198M |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $209M | 2.9% |
9,011,651
| – | – |
|
|
6
Cytek Biosciences
CTKB
$562M
| $206M | 2.85% |
+9,607,028
| New | +$226M |
|
7
Atea Pharmaceuticals
AVIR
$373M
| $190M | 2.64% |
5,427,655
+59,204
| +1% | +$1.64M |
|
8
Janux Therapeutics
JANX
$907M
| $188M | 2.6% |
8,670,644
| – | – |
|
9
Vor Biopharma
VOR
$1.08B
| $174M | 2.42% |
556,049
| – | – |
|
|
JBIO
10
Jade Biosciences
JBIO
$1.18B
| $173M | 2.4% |
236,114
| – | – |
|
|
ICVX
11
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $171M | 2.37% |
+5,779,347
| New | +$196M |
|
|
DICE
12
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $171M | 2.36% |
+5,208,911
| New | +$177M |
|
|
CNTB
13
Connect Biopharma Holdings
CNTB
$130M
| $169M | 2.35% |
6,991,003
| – | – |
|
14
Nkarta
NKTX
$154M
| $156M | 2.16% |
5,605,129
| – | – |
|
15
Acumen Pharmaceuticals
ABOS
$155M
| $145M | 2.01% |
+9,770,773
| New | +$163M |
|
16
TG Therapeutics
TGTX
$8.28B
| $136M | 1.89% |
4,098,332
+755,589
| +23% | +$23.4M |
|
17
Travere Therapeutics
TVTX
$5.3B
| $136M | 1.89% |
5,614,428
| – | – |
|
18
Tyra Biosciences
TYRA
$1.84B
| $127M | 1.76% |
+7,236,454
| New | +$138M |
|
19
MacroGenics
MGNX
$237M
| $124M | 1.72% |
5,943,594
| – | – |
|
|
ITOS
20
DELISTED
iTeos Therapeutics
ITOS
| $119M | 1.65% |
4,417,259
| – | – |
|
|
DAWN
21
DELISTED
Day One Biopharmaceuticals
DAWN
| $118M | 1.63% |
4,965,588
| – | – |
|
|
IMGN
22
DELISTED
Immunogen Inc
IMGN
| $104M | 1.45% |
18,417,458
| – | – |
|
23
Phathom Pharmaceuticals
PHAT
$938M
| $100M | 1.39% |
3,115,008
| – | – |
|
24
Vaxcyte
PCVX
$7.7B
| $98.9M | 1.37% |
3,896,865
+31,057
| +0.8% | +$753K |
|
|
ETNB
25
DELISTED
89bio
ETNB
| $97.3M | 1.35% |
4,965,769
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, RA Capital Management held 109 positions worth $7.22B, up 16% from $6.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
RA Capital Management deployed $1.27B of net new capital in Q3 2021, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Climb Bio: 13,150,849 shares worth $236M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Novavax, an estimated $102M trimmed.
- RA Capital Management's largest Q3 2021 buy was Climb Bio: 13,150,849 shares worth $236M.
- RA Capital Management added most to Ascendis Pharma A/S in Q3 2021, an estimated $79.6M increase.
- RA Capital Management's biggest Q3 2021 reduction was Novavax, cutting an estimated $102M.
- RA Capital Management fully exited Axsome Therapeutics in Q3 2021, selling an estimated $112M.
- RA Capital Management's ten largest holdings make up 45% of its $7.22B portfolio in Q3 2021.
- RA Capital Management opened 17 new positions and closed 14 in Q3 2021.
- RA Capital Management's portfolio value rose 16% quarter-over-quarter to $7.22B.
Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.